William H. Hildebrand
Fondateur chez Pure Protein LLC
Profil
William H.
Hildebrand is the founder of MHC Biologics LLC (founded in 2007), Pure Protein LLC (founded in 1999), and Pure MHC LLC (founded in 2013).
He holds the title of Chief Scientist at Pure Protein LLC and Chief Scientist-Target Discovery at Pure MHC LLC.
Currently, he is an Associate Professor at the University of Oklahoma.
Dr. Hildebrand received his undergraduate degree from St. Mary's University in 1983, his graduate degree from Southern Illinois University in 1986, and his doctorate from Southern Illinois University in 1989.
Postes actifs de William H. Hildebrand
| Sociétés | Poste | Début |
|---|---|---|
Pure Protein LLC
 Pure Protein LLC Pharmaceuticals: MajorHealth Technology Pure Protein LLC specializes in immunology tools for diagnostics, drug and vaccine development, and high-yield protein production. It operates as a biopharmaceutical company, produces soluble human leukocyte antigen (sHLA) proteins and custom products in various human and animal cell lines. The firm provides sHLA class I and II proteins for use in transplantation, drug target discovery, and bio-therapeutic development, as well as diagnostic and therapeutic reagents for use in immunology research and development. The company was founded by William Hildebrand in 1999 and is headquartered in Austin, TX. | Fondateur | 01/01/1999 |
| University of Oklahoma | Corporate Officer/Principal | 29/07/2009 |
Pure MHC LLC
 Pure MHC LLC Medical SpecialtiesHealth Technology Pure MHC LLC provides diagnostics and therapeutics technology services. It offers epitope discovery solution where it identifies peptide epitopes that are upregulated in the affected state and validated as ligands presented by human leukocyte antigen (HLA) molecules and T cell receptor mimics (TCRms) technology, monoclonal antibodies that function like T-cell receptor. The firm also provides regulatory compliance support and existing target validation and tissue distribution services. The company was founded by William Hildebrand in 2013 and is headquartered in Austin, TX. | Fondateur | 01/01/2013 |
Anciens postes connus de William H. Hildebrand
| Sociétés | Poste | Fin |
|---|---|---|
MHC Biologics LLC
 MHC Biologics LLC BiotechnologyHealth Technology MHC Biologics, LLC, an emerging biotechnology company, has developed a unique and proprietary portfolio of breakthrough technologies that can be used in the development and design of novel therapeutics, including therapeutic vaccines for cancer and other diseases. MHC Biologics has been founded to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz, Texas Tech University Pharmacy School and Receptor Logic, Ltd., and Dr. William Hildebrand, Oklahoma University Health Science Center and Pure Vaccine Solutions, LLC. These technology 'tools' can be utilized for immunology-based cancer diagnosis and treatment. Funded and managed by life sciences venture firm, Emergent Technologies, Inc., MHC Biologics is actively seeking commercialization partners. MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers - peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics' unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases. | Fondateur | - |
Formation de William H. Hildebrand
| St. Mary's University | Undergraduate Degree |
| Southern Illinois University | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Pure Protein LLC
Pure Protein LLC Pharmaceuticals: MajorHealth Technology Pure Protein LLC specializes in immunology tools for diagnostics, drug and vaccine development, and high-yield protein production. It operates as a biopharmaceutical company, produces soluble human leukocyte antigen (sHLA) proteins and custom products in various human and animal cell lines. The firm provides sHLA class I and II proteins for use in transplantation, drug target discovery, and bio-therapeutic development, as well as diagnostic and therapeutic reagents for use in immunology research and development. The company was founded by William Hildebrand in 1999 and is headquartered in Austin, TX. | Health Technology |
Pure MHC LLC
Pure MHC LLC Medical SpecialtiesHealth Technology Pure MHC LLC provides diagnostics and therapeutics technology services. It offers epitope discovery solution where it identifies peptide epitopes that are upregulated in the affected state and validated as ligands presented by human leukocyte antigen (HLA) molecules and T cell receptor mimics (TCRms) technology, monoclonal antibodies that function like T-cell receptor. The firm also provides regulatory compliance support and existing target validation and tissue distribution services. The company was founded by William Hildebrand in 2013 and is headquartered in Austin, TX. | Health Technology |
MHC Biologics LLC
MHC Biologics LLC BiotechnologyHealth Technology MHC Biologics, LLC, an emerging biotechnology company, has developed a unique and proprietary portfolio of breakthrough technologies that can be used in the development and design of novel therapeutics, including therapeutic vaccines for cancer and other diseases. MHC Biologics has been founded to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz, Texas Tech University Pharmacy School and Receptor Logic, Ltd., and Dr. William Hildebrand, Oklahoma University Health Science Center and Pure Vaccine Solutions, LLC. These technology 'tools' can be utilized for immunology-based cancer diagnosis and treatment. Funded and managed by life sciences venture firm, Emergent Technologies, Inc., MHC Biologics is actively seeking commercialization partners. MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers - peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics' unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases. | Health Technology |